78. Hypopituitarism
462 clinical trials,   346 drugs   (DrugBank: 45 drugs),   41 drug target genes,   80 drug target pathways

Searched query = "Hypopituitarism", "Anterior pituitary hypothyroidism", "Syndrome of abnormal secretion of gonadotropin", "Hyposecretion of gonadotropins", "Adrenocorticotropic hormone deficiency", "ACTH deficiency", "Thyroid-stimulating hormone deficiency", "TSH deficiency", "Growth hormone deficiency", "GH deficiency", "GHD", "CGHD", "AGHD", "Prolactin deficiency", "PRL deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04465565
(ClinicalTrials.gov)
December 20203/7/2020Fluids Administration During Combined Clonidine-Arginine Growth Hormone Stimulation TestFluids Administration During Combined Clonidine-Arginine Growth Hormone Stimulation Test- Randomized, 2 Arms, Controlled StudyGrowth Hormone DeficiencyProcedure: 9% Sodium Chloride (NaCl) IVRabin Medical CenterNULLNot yet recruiting7 Years16 YearsAll120N/AIsrael
2JPRN-UMIN000027260
2017/02/0607/05/2017Analysis of Airway Inflammatory state alteration after intravenous L-Arginine loading Children who are required growth hormone (GH) stimulation tests to diagnose GH deficiency. These are children whose heights are two standard deviations (SD) below the mean for age and sex, and/or whose growth velocities are 1.5 SD below the mean for age and sex over 2 years' follow-up, or whose pediatric endocrinologists order growth hormone (GH) stimulation test for another reasons.Dosing 500mg/kg L-arginine (maximal dose 30g) intravenous drip in 30minutesOsaka City University Graduate School of MedicineNULL2years-old15years-oldMale and Female15Not selectedJapan
3NCT00720902
(ClinicalTrials.gov)
February 200716/6/2008Adult Growth Hormone Deficiency and Cardiovascular RiskAssessment of Cardiovascular Risk Markers in GH Deficient Patients With Nonsecreting Pituitary AdenomasGrowth Hormone DeficiencyProcedure: Blood draws;Drug: Growth hormone releasing hormone (GHRH) and arginine;Procedure: Carotid ultrasound;Procedure: MRI;Procedure: Endothelial cell biopsyColumbia UniversityNULLTerminated19 Years65 YearsBoth8N/AUnited States
4NCT00468624
(ClinicalTrials.gov)
December 20042/5/2007Effect of Pegvisomant on GH/IGF-I Relationship in GHDA Study of the Relationship Between Serum Growth Hormone (GH) and Insulin-Like Growth Factor One (IGF-I) in Patients With Severe Adult Growth Hormone Deficiency (AGHD)Severe Adult Growth Hormone DeficiencyDrug: pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks;Procedure: GH sampling - every 20 min over 24 hours after each limb (pegvisomant/placebo);Procedure: blood sampling before and after pegvisomant/placebo;Procedure: arginine stimulation test after each limbChristie Hospital NHS Foundation TrustNULLTerminated18 Years70 YearsBothN/AUnited Kingdom
5NCT01060488
(ClinicalTrials.gov)
January 200429/1/2010Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone DeficiencyA Phase III, Multicentric, Open-label, Randomised, Comparative, Parallel Group Study of (GHRH + Arginine) Combination Test vs. Insulin Tolerance Test (ITT) in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)Growth Hormone DeficiencyOther: GHRH+Arg, GHRH+Arg, ITT;Other: ITT, ITT, GHRH+Arg.Merck KGaANULLCompleted18 Years60 YearsBoth69Phase 3France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03018886
(ClinicalTrials.gov)
May 20016/1/2017Diagnosing Adult Growth Hormone DeficiencyDiagnosis of Adult Growth Hormone Deficiency With Growth Hormone Releasing Hormone Plus Arginine Stimulation TestGrowth Hormone DeficiencyOther: GHRH plus arginine testHelsinki University Central HospitalNULLCompleted16 Years80 YearsAll160N/AFinland
7NCT00134420
(ClinicalTrials.gov)
February 200122/8/2005Growth Hormone and Chromosome 18q- and Abnormal GrowthGrowth Hormone Trial for Children With 18q- and Abnormal GrowthLoss of Chromosome 18q;Growth Hormone DeficiencyDrug: Nutropin AQ;Procedure: Arginine and Clonidine Stimulation Testing;Procedure: Growth Factors Laboratory Testing;Procedure: Neuropsychological TestingThe University of Texas Health Science Center at San AntonioSouth Texas Veterans Health Care System;Genentech, Inc.CompletedN/A18 YearsBoth20Phase 3United States
8EUCTR2010-018781-23-NL
(EUCTR)
17/02/2010Diagnose of GH-deficiency: comparing the dietary-protein test with conventional Growth Hormone Stimulation TestsDiagnose of GH-deficiency: comparing the dietary-protein test with conventional Growth Hormone Stimulation Tests To investigate if there is a correlation between the peak GH concentrations after ingestion of gelatin protein and the peak GH concentrations after the two standard tests (GHST) in order to discriminate growth hormone deficiency (GHD) and non-GHD. To investigate the differences in coefficient of variation between the different tests (arginine, clonidine, protein). To investigate the frequency of side effects in the different tests (arginine, clonidine, protein).
MedDRA version: 12.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency
Product Name: Gelatin
Product Code: 3
Product Name: Arginin
Product Code: 1
Trade Name: Clonidine HCl CF 0,150 mg, tabletten
Product Name: Clonidine
Product Code: 2
INN or Proposed INN: Clonidin
Other descriptive name: CLONIDINE HYDROCHLORIDE
Top Institute Food and NutritionNULLNAFemale: yes
Male: yes
Netherlands